Entry Point Capital, LLC Monte Rosa Therapeutics, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GLUE
# of Institutions
83Shares Held
43.9MCall Options Held
141KPut Options Held
31.2K-
Nea Management Company, LLC Timonium, MD7.69MShares$64.2 Million3.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.6MShares$55.1 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.79MShares$48.3 Million0.46% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$41 Million0.28% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.66MShares$22.2 Million0.55% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $390M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...